Can a new approach improve outcomes for patients with metastatic triple negative breast cancer?

This study will test a new combination therapy for metastatic triple negative breast cancer. It will help researchers decide if giving a combination of the immunotherapy drug, atezolizumab, and the chemotherapy drug, carboplatin, works better to stop the growth and spread of cancer cells than the standard therapy.